PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

Trial Details

NCT ID

NCT06157151

Phase

PHASE2

Sponsor

Precigen, Inc

Status

RECRUITING

Cancer Type

Cervical Cancer

Interventions

• PRGN-2009 plus Pembrolizumab

Locations (sample)

• Little Rock, Arkansas, United States|34.74648,-92.28959
• Bethesda, Maryland, United States|38.98067,-77.10026
• Seattle, Washington, United States|47.60621,-122.33207

Key Eligibility Criteria

• Age 18 years and older.
• Recurrent or metastatic cervical cancer (histologically or cytologically confirmed)
• Must have been treated with pembrolizumab, either as monotherapy or in combination, for atleast 6 weeks.
• Subjects must have histologically or cytologically confirmed HPV positive disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.